- Home
- MYGN vs TMCR Comparison
MYGN vs TMCR Comparison
Compare MYGN & TMCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MYGN | TMCR |
|---|---|---|
| Founded | 1991 | 2022 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Precious Metals |
| Sector | Health Care | Basic Materials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 372.1M | 385.0M |
| IPO Year | 1996 | 2025 |
Fundamental Metrics
Financial Performance| Metric | MYGN | TMCR |
|---|---|---|
| Price | $4.08 | $2.67 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 9 | 2 |
| Target Price | $4.05 | ★ $11.83 |
| AVG Volume (30 Days) | ★ 2.0M | 115.4K |
| Earning Date | 11-02-2026 | 11-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $771,400,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $5.47 | $1,083.90 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 2.33 | N/A |
| 52 Week Low | $2.74 | $2.77 |
| 52 Week High | $8.59 | $8.75 |
Technical Indicators
Market Signals| Indicator | MYGN | TMCR |
|---|---|---|
| Relative Strength Index (RSI) | 53.52 | 23.63 |
| Support Level | $2.89 | N/A |
| Resistance Level | $4.89 | $5.50 |
| Average True Range (ATR) | 0.24 | 0.58 |
| MACD | -0.02 | -0.06 |
| Stochastic Oscillator | 22.78 | 0.00 |
Price Performance
Historical ComparisonAbout MYGN Myriad Genetics Inc.
Myriad Genetics Inc is a molecular diagnostics and precision medicine company committed to advancing health and well-being for all. The company develops and commercializes molecular tests that help patients and providers uncover genetic insights. Its tests assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties, supporting earlier detection, more precise treatment, and lowering healthcare costs. Its tests include BRACAnalysis CDx, EndoPredict, FirstGene, Foresight, GeneSight, MyChoice CDx, MyRisk (cancer treatment), MyRisk (cancer risk), Prequel, Precise Tumor, Prolaris, and SneakPeek. The company operates in the US and Rest of World, with maximum revenue from the US.
About TMCR The Metals Royalty Company Inc. Common Stock
The Metals Royalty Co Inc is engaged in the acquisition and management of critical metals and mineral royalties, streams, and other similar interests. It is focused on providing capital to support mineral security and independence in North America in support of accelerating domestic industry growth, including energy, defense, and re-industrialization. The company derives royalty income from its business activities.